DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells-Reference-Cited by-同舟云学术

DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells

Published:2018-10-31 Issue:7732 Volume:563 Page:522-526
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

He Yizhou Joseph,Meghani Khyati,Caron Marie-Christine,Yang Chunyu,Ronato Daryl A.,Bian Jie,Sharma Anchal,Moore Jessica,Niraj Joshi,Detappe Alexandre,Doench John G.,Legube Gaelle,Root David E.,D’Andrea Alan D.,Drané Pascal,De Subhajyoti,Konstantinopoulos Panagiotis A.,Masson Jean-Yves,Chowdhury Dipanjan

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-018-0670-5.pdf

Reference47 articles.

1. Bolton, K. L. et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307, 382–390 (2012).

2. Vencken, P. M. et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann. Oncol. 22, 1346–1352 (2011).

3. Yang, D. et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306, 1557–1565 (2011).

4. Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17, 688–695 (2010).

5. Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243–254 (2010).

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes;Expert Review of Anticancer Therapy;2024-09-03

2. Large-scale copy number alterations are enriched for synthetic viability in BRCA1/BRCA2 tumors;Genome Medicine;2024-08-28

3. 53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancer;Nature Communications;2024-08-06

4. GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway;Oncogene;2024-08-03

5. BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality;Journal of Clinical Investigation;2024-07-15